Use this guide one step at a time.
Lung cancer planning depends first on whether the tumor is non-small cell or small cell, how far it has spread, and whether enough tissue is available for recommended testing. These details can change the order and type of treatment.
Key points
- Before advanced non-small cell treatment.
Subtypes and biomarkers
The two main groups are non-small cell lung cancer and small cell lung cancer. Non-small cell disease includes adenocarcinoma, squamous cell carcinoma, and less common types; it is staged from I through IV. Small cell disease usually grows and spreads more quickly and is commonly described as limited-stage or extensive-stage. This distinction shapes surgery, radiation, chemotherapy, and immunotherapy choices. In non-small cell lung cancer, especially advanced disease, tumor biomarker testing can find changes that match targeted treatments. Examples include alterations involving EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, and HER2, although the useful panel depends on the specimen and current treatment setting. Biomarker testing uses tumor tissue or sometimes blood; a negative blood result may not settle the question if tumor testing remains possible. Small cell lung cancer generally relies more on histology and stage than on routine targeted-treatment biomarkers.
What is lung cancer?
Non-small cell lung cancer accounts for most lung cancers and includes adenocarcinoma, squamous cell carcinoma, and other subtypes. Small cell lung cancer tends to grow and spread more quickly and is usually described as limited-stage or extensive-stage disease. Tobacco smoke is the leading risk factor, but lung cancer also occurs in people who never smoked. Radon, secondhand smoke, occupational exposures, air pollution, prior radiation, and family or personal history can contribute. Low-dose CT screening is recommended for certain people at high risk based on age and smoking history; it differs from testing prompted by symptoms. Pathology establishes the type, while molecular testing can identify changes that guide targeted therapy in non-small cell disease. PD-L1 testing can help guide immunotherapy. Because the lungs and nearby lymphatic structures are central to breathing, both disease and treatment can affect respiratory function. Care depends on type, stage, biomarkers, health, lung function, and preferences.
Signs and symptoms
Lung cancer may cause no symptoms early. Possible warning signs include a cough that does not go away or changes, coughing up blood, hoarseness, chest pain, shortness of breath, wheezing, repeated pneumonia or bronchitis, unusual fatigue, loss of appetite, and unexplained weight loss. A tumor pressing on nearby structures can cause facial or neck swelling or trouble swallowing. Disease that has spread may cause bone pain, headache, weakness, balance changes, seizures, or jaundice, depending on the affected site. Small cell and non-small cell cancers can produce similar symptoms. These findings can also result from infections, chronic lung disease, heart conditions, or other noncancer causes. Persistent or worsening respiratory symptoms, especially coughing blood or new breathing difficulty, warrant prompt medical assessment rather than self-diagnosis.
Diagnosis and staging
Evaluation may include history, examination, chest imaging, and comparison with prior scans. CT defines the lung abnormality and nearby structures; PET-CT, brain MRI, bone imaging, or other tests may assess spread when indicated. Cancer is confirmed by examining cells or tissue obtained through bronchoscopy, needle biopsy, thoracentesis, lymph-node sampling, or surgery. Pathology distinguishes non-small cell from small cell cancer and identifies subtype. For non-small cell disease, broad molecular testing and PD-L1 testing are often essential before systemic treatment, especially in advanced disease. TNM staging describes tumor size and local invasion, lymph nodes, and metastasis, producing stages I through IV. Small cell lung cancer is commonly grouped as limited or extensive, alongside TNM information. Pulmonary-function tests and general fitness help determine whether surgery or radiation is feasible. Treatment depends on histology, stage, biomarkers, lung function, overall health, and preferences. Sampling a metastatic site may provide both diagnosis and staging information.
Established treatment paths
Early non-small cell lung cancer may be treated with surgery, stereotactic body radiation therapy for people who cannot have surgery, or other radiation approaches. Chemotherapy, immunotherapy, targeted therapy, or combinations may be given before or after surgery according to stage and tumor features. Locally advanced disease often uses chemotherapy with radiation, sometimes followed by immunotherapy. Metastatic non-small cell cancer is treated according to molecular alterations, PD-L1 expression, histology, symptoms, and prior treatment. Actionable changes can make an oral targeted drug the preferred initial treatment; other cancers may receive immunotherapy alone or with chemotherapy. Small cell lung cancer usually receives platinum-based chemotherapy with another drug; radiation is added for limited-stage disease, and immunotherapy is used in many extensive-stage settings. Radiation can also relieve pain, airway blockage, bleeding, or brain metastases. Smoking cessation support can improve health and treatment tolerance at any stage. Clinical trials can expand options. The plan depends on cancer type, stage, biomarkers, lung and organ function, coexisting conditions, and goals, with repeat imaging and symptom review used to assess response.
Supportive care
Supportive care should address breathing from the start. The team can evaluate breathlessness, cough, airway blockage, pleural fluid, chest pain, oxygen needs, anxiety that worsens breathing, and treatment-related lung inflammation. Pulmonary rehabilitation, pacing, positioning, and selected procedures or medicines may help, depending on the cause. Nutrition support can address low appetite and weight loss, while physical therapy can protect strength during treatment. Smoking-cessation medicines and counseling remain useful after diagnosis. Radiation may cause swallowing pain; chemotherapy can cause infection risk, nausea, or neuropathy; immunotherapy can inflame organs and requires timely reporting of new symptoms. Palliative care can work alongside tumor treatment at any stage.
Profiles documenting lung cancer care
These profiles mention a matching cancer specialty in their published materials. Browse their locations, reported services, and practical details.
Sources
Source information checked: 2026-10-01. The links below identify the public and clinic-provided materials used for this page.
- NCI: Lung Cancer ↗Checked 2026-09-29
- NCI: Non-Small Cell Lung Cancer Treatment ↗Checked 2026-09-29
- NCI: Small Cell Lung Cancer Treatment ↗Checked 2026-09-29
- NCI: Biomarker Testing for Cancer Treatment ↗Checked 2026-10-01
- NCI: Side Effects of Cancer Treatment ↗Checked 2026-10-01
How Cancer Clinic Finder compiles information · Suggest a factual correction
